胃癌药物市场（依治疗层级、治疗线、通路、给药途径、剂型和治疗类型划分）－全球预测，2025-2032

预计到 2032 年，胃癌药物市场规模将成长至 66.3 亿美元，复合年增长率为 6.32%。

说明不断发展的临床和商业生态系统以及影响胃癌治疗的相关人员的策略重点

胃癌是一个复杂的治疗领域，生物学、临床实践和医疗保健系统政策相互交织，共同影响患者的治疗结果。近年来，由于分子生物学的阐明、联合治疗的广泛应用以及免疫疗法和分子标靶药物的引入，临床医生对胃癌的诊断、分期和治疗方式迅速演变。这些发展改变了治疗途径，为药物开发商、支付方和医疗保健提供者创造了独特的机会和挑战，使其能够适应新的疗效和安全性特征以及不断变化的治疗标准。

本摘要总结了影响治疗开发和商业化的最重要趋势。它强调了不断变化的临床模式、商业性动态和监管模式，这些趋势正在重新定义胃肿瘤学的价值获取。本摘要着重于可操作的洞察而非原始的市场预测，强调了临床证据、治疗可近性和策略定位之间的关联。其目的是为高阶主管、临床领导者和相关人员提供简洁而全面的指导，以优先考虑投资、优化上市方案，并预测将影响专案可行性和病患可及性的近期曲折点。

精准医疗、免疫肿瘤学的进步以及不断变化的监管和报销奖励如何从根本上重塑胃癌治疗模式

胃癌治疗领域正在经历一场变革性的转变，涵盖科学创新、监管格局和治疗交付模式。在科学方面，精准肿瘤学正在加速融入标准工作流程，分子亚型分析和生物标记主导的患者选择已常规反映在治疗方法决策和试验设计中。这种个人化治疗趋势提升了伴随诊断的重要性，并催生了对能够证明跨明确生物标记层级效用的临床试验的需求。同时，免疫肿瘤学正扩展到胃癌领域，包括查核点抑制剂和联合方案，旨在利用标靶药物和免疫微环境的协同作用。

法律规范正在适应这些科学进步，简化基于替代终点的加速核准途径，以应对高未满足需求人群的需求，同时强调核准后证据的产生以确认临床效用。支付方和医疗系统正在製定基于结果的合约机制，并审查真实世界证据以做出覆盖决策。这些趋势正在促进协作模式的发展，製造商、医疗保健提供者和诊断开发人员将在证据产生和报销策略方面展开合作。这些转变正在重塑整个价值链的临床试验重点、商业模式和投资策略。

评估近期关税改革和贸易政策转变对治疗投入和最终产品的策略供应链、定价和准入的影响

2025年，影响药品、零件和相关生技药品投入的关税政策为全球供应链和商业营运带来了新的复杂性。关税调整可能会增加进口活性药物原料药、研究耗材和某些成品的到岸成本，从而对製造足迹和筹资策略造成压力。拥有全球分布供应链的製造商应审查供应商合同，并考虑近岸外包、双重采购和增加库存缓衝等方案，以减轻关税导致的价格波动风险。

累积影响将波及采购、定价和市场进入等各个面向。依赖国际供应商的医院和医疗系统可能面临更高的采购成本，这可能导致更严格的配方谈判和更严格的卫生技术评估。製造商将被奖励优化生产布局，并投资于供应链透明度，以支持与付款人进行成本控制讨论。同时，公司可能会加快关于基于价值的合约的讨论，将价格与产量脱钩，并将报销重点放在已证实的临床结果上。这种转变也为能够展示抗关税采购和敏捷品质保证流程的区域製造伙伴关係和供应商创造了机会。最终，关税变化将提昇在受影响市场中支持供应链敏捷性和持久准入的证据的战略重要性。

将治疗层级、治疗路线、分销管道、给药途径、剂型和治疗类型与临床和商业性影响联繫起来的细分见解

对胃癌治疗领域进行细分，有助于明确临床价值和商业机会的交会点，并揭示不同的产品属性如何影响产品采用和定位。根据治疗层级，生物製药（包括细胞激素和单株抗体）、化疗（包括Fluoropyrimidines、含铂类药物和紫杉烷类）、免疫疗法（包括癌症疫苗和查核点抑制剂）以及标靶治疗（包括 Her2 抑制剂和 Vegf 抑制剂）各自具有独特的开发途径和证据要求，并以独特的方式与诊断、联合策略和安全监测相互作用。生物製药製剂亚类之间的区别对于製造复杂性和监管预期至关重要，而化疗的既定作用是许多组合方案的基础，并影响治疗方案的决策。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• FDA核准FGFR2b标靶单株抗体，助力胃癌精准治疗
• PD-1/PD-L1 免疫查核点抑制剂在晚期胃癌一线治疗通讯协定的应用日益增多
• 基于ctDNA的液态生物检体检测的出现，可用于即时监测胃癌患者的治疗反应
• HER2标靶蛋白酪氨酸激酶抑制剂的扩展为HER2阳性胃肿瘤提供了新的第一线治疗
• 增加对胃癌免疫治疗中双查核点路径的双特异性抗体候选药物的投资
• 微生物组调节疗法因增强胃癌标准化疗疗效而受到关注
• 生物製药公司与诊断公司进行策略合作，开发针对胃癌的伴随诊断药物
• Claudin 18.2 标靶 CAR-T 细胞疗法在难治性胃癌病例中显示出良好的持久疗效

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 胃癌药物市场（依治疗层级）

• 生物製药
  • 细胞激素
  • 单株抗体
• 化疗
  • Fluoropyrimidines
  • 铂类药物
  • 紫杉烷类
• 免疫疗法
  • 癌症疫苗
  • 查核点抑制剂
• 标靶治疗
  • HER2抑制剂
  • VEGF抑制剂

第九章胃癌药物市场（依治疗线）

• 首选药物
• 二线药物
• 三线或更高版本

第 10 章胃癌药物市场按分销管道

• 医院药房
• 零售药局

第11章胃癌药物市场依给药途径

• 静脉
• 口服
• 皮下

第十二章胃癌药物市场（按剂型）

• 胶囊
• 冻干粉
• 预填充式注射器
• 药片

第十三章胃癌药物市场（依治疗类型）

• 联合治疗
• 单一疗法

第十四章胃癌药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章胃癌药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 胃癌药物市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

The Gastric Cancer Drugs Market is projected to grow by USD 6.63 billion at a CAGR of 6.32% by 2032.

A concise orientation to the evolving clinical and commercial ecosystem shaping gastric cancer therapeutics and strategic priorities for stakeholders

Gastric cancer remains a complex therapeutic area where biology, clinical practice, and health system policy intersect to shape patient outcomes. Recent years have seen a rapid evolution in how clinicians diagnose, stage, and treat gastric malignancies, driven by improved molecular characterization, broader adoption of multimodal therapy, and the introduction of immune and targeted agents. These developments have altered treatment pathways and created distinct opportunities and challenges for pharmaceutical developers, payers, and providers as they adapt to new efficacy and safety profiles and shifting standards of care.

This summary synthesizes the most relevant trends influencing therapeutic development and commercialization. It highlights changes in clinical paradigms, commercial dynamics, and regulatory patterns that are redefining value capture in gastric oncology. By focusing on actionable insights rather than raw market estimates, the narrative emphasizes the nexus between clinical evidence, treatment access, and strategic positioning. The aim is to equip executives, clinical leaders, and investor stakeholders with a concise but comprehensive orientation to the landscape so they can prioritize investments, refine go-to-market approaches, and anticipate near-term inflection points that will affect program viability and patient access.

How precision medicine, immuno-oncology advances, and evolving regulatory and reimbursement incentives are fundamentally reshaping gastric cancer treatment paradigms

The therapeutic landscape for gastric cancer is experiencing transformative shifts that span scientific innovation, regulatory approaches, and care delivery models. On the scientific front, the integration of precision oncology into standard workflows has accelerated; molecular subtyping and biomarker-driven patient selection are now routinely informing therapeutic decisions and trial design. This movement toward individualized therapy has elevated the importance of companion diagnostics and created demand for trials that demonstrate benefit in well-defined biomarker strata. Concurrently, immuno-oncology has extended into gastric cancer with checkpoint inhibitors and combinatorial regimens that aim to leverage synergy between targeted agents and the immune microenvironment.

Regulatory frameworks are adapting to these scientific advances by streamlining pathways for accelerated approval based on surrogate endpoints in populations with high unmet need, while simultaneously stressing post-approval evidence generation to confirm clinical benefit. Payers and health systems are responding by developing outcome-based contracting mechanisms and by scrutinizing real-world evidence to guide coverage decisions. These dynamics are catalyzing collaborative models where manufacturers, providers, and diagnostic developers align on evidence generation and reimbursement strategies. Together, these shifts are reshaping clinical trial priorities, commercial models, and investment strategies across the value chain.

Assessing the strategic supply chain, pricing, and access implications resulting from recent tariff changes and trade policy shifts affecting therapeutic inputs and finished products

In 2025, tariff policies affecting pharmaceuticals, components, and related biologics inputs introduced a new layer of complexity across global supply chains and commercial operations. Tariff adjustments have the potential to increase landed costs for imported active pharmaceutical ingredients, laboratory consumables, and certain finished formulations, exerting pressure on manufacturing footprints and procurement strategies. Manufacturers with globally dispersed supply chains must reassess supplier contracts and consider options such as nearshoring, dual sourcing, and increased inventory buffering to mitigate exposure to tariff-driven price volatility.

The cumulative impact is felt across procurement, pricing, and market access. Hospitals and health systems that rely on international suppliers may face higher acquisition costs, which can translate into tighter formulary negotiations and more rigorous health technology assessments. Manufacturers are incentivized to optimize manufacturing locality and to invest in supply chain transparency to support cost-containment discussions with payers. In parallel, companies may accelerate conversations about value-based agreements that decouple price from volume and focus reimbursement on demonstrated clinical outcomes. These shifts also create opportunities for regional manufacturing partnerships and for suppliers that can demonstrate tariff-resilient sourcing and rapid quality assurance processes. Ultimately, tariff changes increase the strategic importance of supply chain agility and evidence that supports durable access in affected markets.

Segment specific insights that connect therapeutic class, line of therapy, distribution pathway, administration route, dosage formulation, and therapy composition to clinical and commercial implications

Segmenting the gastric cancer therapeutics landscape clarifies where clinical value and commercial opportunity intersect, and it highlights how different product characteristics influence adoption and positioning. Based on therapeutic class, Biologics including cytokines and monoclonal antibodies, Chemotherapy including fluoropyrimidines, platinum-based agents, and taxanes, Immunotherapy encompassing cancer vaccines and checkpoint inhibitors, and Targeted Therapy with Her2 inhibitors and Vegf inhibitors each have distinct development pathways and evidence requirements, and they interact with diagnostics, combination strategies, and safety monitoring in unique ways. The differentiation between biologic subclasses matters for manufacturing complexity and regulatory expectations, while the established roles of chemotherapy anchor many combination regimens and influence line-of-therapy decisions.

Based on treatment line, differences between first line, second line, and third line or later therapies govern trial design, comparator selection, and the magnitude of unmet need that a new therapy must address. First-line innovations typically require broader safety tolerability and demonstrable improvement in survival or quality of life, whereas later-line agents may gain approval based on smaller, biomarker-enriched populations with clinically meaningful responses. Based on distribution channel, the split between hospital pharmacies and retail pharmacies affects channel economics, patient access points, and the logistics of reimbursement and adherence support. Based on route of administration, the divergence among intravenous, oral, and subcutaneous modalities has implications for site-of-care, patient convenience, adherence, and cost structures, with oral and subcutaneous options often enabling outpatient management and potential shifts away from infusion center utilization.

Based on dosage form, considerations around capsules, lyophilized powder, pre-filled syringe, and tablets extend beyond patient preferences to stability, cold chain logistics, and compounding requirements, which in turn influence procurement and inventory policies. Finally, based on therapy type, the strategic choices between combination therapy and monotherapy drive clinical development complexity, regulatory interactions, and commercial narratives; combination regimens can deliver incremental efficacy but require careful safety management and co-development coordination. Taken together, these segmentation lenses provide a structured framework to prioritize development programs, design differentiated clinical trials, and craft market access strategies that align product attributes with clinical practice and payer expectations.

How regional regulatory diversity, payer frameworks, and healthcare infrastructure dictate differentiated market access and commercialization strategies across major global regions

Regional dynamics play a pivotal role in shaping development priorities, regulatory strategy, and commercialization approaches for gastric cancer therapies. In the Americas, regulatory convergence and established oncology networks support rapid adoption of innovations that demonstrate clear clinical benefit, yet payer scrutiny and value assessment frameworks require robust outcomes evidence and price-value alignment. Health systems in the region are also increasingly receptive to real-world evidence generation and value-based purchasing pilots that can enable earlier patient access while managing budget impact.

In Europe, Middle East & Africa, heterogeneity across regulatory environments and reimbursement pathways necessitates tailored market access strategies and flexible pricing models. While some jurisdictions exhibit strict health technology assessment protocols with cost-effectiveness thresholds, others prioritize access through managed entry agreements or conditional reimbursement linked to post-market evidence. Capacity constraints and variations in diagnostic availability in parts of the region underscore the need for deployment plans that include diagnostic enablement and capacity building to realize the full potential of targeted therapies. In Asia-Pacific, high incidence rates in certain countries, combined with rapidly modernizing clinical infrastructure, create strong demand for therapies that address region-specific molecular epidemiology. Regulatory authorities across Asia are increasingly harmonizing pathways and engaging in expedited review processes for priority medicines, while local manufacturing and licensing partnerships remain central to scaling access and managing commercial risk. Across all regions, alignment between evidence generation, pricing approaches, and delivery infrastructure is essential to convert clinical innovation into broader population impact.

Insights into how research focus, partnership structures, diagnostic integration, and manufacturing strategies differentiate company competitive positioning in gastric cancer therapeutics

Company strategies in gastric cancer therapeutics are diverging along research intensity, portfolio breadth, and partnership models. Some organizations concentrate R&D investment on next-generation targeted agents and biomarker discovery, prioritizing programs that enable narrow indication approvals but high clinical impact. Others pursue combination regimens that pair established chemotherapeutics with immuno-modulatory agents to enhance response durability in broader populations. A growing subset of companies is emphasizing diagnostic co-development and commercial bundling to support precise patient selection and to accelerate reimbursement acceptance.

Commercially, leading firms are experimenting with differentiated pricing approaches, evidence generation partnerships, and lifecycle management strategies that extend utility through new dosage forms or administration routes. Strategic alliances between biotechnology innovators and larger specialty pharmaceutical companies continue to be a dominant model for scaling manufacturing, regulatory submissions, and global commercialization. Additionally, companies with integrated manufacturing capabilities and regional production footprints are better positioned to navigate trade policy shifts and to respond rapidly to formulary decisions. Across the ecosystem, success increasingly depends on demonstrating meaningful patient benefit in real-world settings and on establishing collaborative arrangements with providers and payers to align incentives around value and access.

Practical and high impact strategic actions for developers and commercial leaders to secure clinical adoption, supply chain resilience, and payer alignment in gastric cancer care

Industry leaders seeking to strengthen their position in gastric cancer therapeutics should prioritize integrated strategies that align scientific differentiation with operational resilience and payer engagement. First, invest early in biomarker discovery and companion diagnostic partnerships to maximize the clinical and commercial returns of targeted and immuno-modulatory programs. Diagnostics are critical enablers of precision labeling and help build compelling dossiers for reimbursement discussions. Second, redesign supply chains for greater flexibility by diversifying sourcing, exploring regional manufacturing options, and implementing digital traceability to mitigate tariff and trade risks while improving procurement predictability.

Third, develop evidence generation plans that combine randomized trials with pragmatic real-world studies to address payer concerns about generalizability and long-term outcomes. Purposeful post-approval data collection can unlock managed entry agreements and outcome-based contracts. Fourth, evaluate administration route and dosage form innovation not only through a clinical lens but also as a commercial lever to shift site-of-care, improve adherence, and reduce total cost of care. Fifth, pursue value-focused pricing strategies and commercial models that emphasize demonstrable improvements in survival, quality of life, or healthcare utilization, enabling constructive dialogues with payers and health systems. By implementing these actions in a coordinated manner, organizations can reduce execution risk and accelerate the translation of clinical advances into sustained patient access.

A transparent multi-source methodology combining clinical evidence review, regulatory and payer analysis, and expert validation to derive robust actionable insights

This research synthesized publicly available clinical literature, regulatory decisions, guideline updates, and expert interviews to build a multi-dimensional perspective on gastric cancer therapeutics. The approach combined qualitative thematic analysis of peer-reviewed clinical studies and conference data with structured interviews of oncologists, pharmacoeconomists, and supply chain specialists to capture operational and access considerations. Regulatory pathways and policy developments were reviewed across major jurisdictions to understand approval trends and post-market evidence expectations, and payer literature was examined to identify common value assessment criteria and contracting practices.

Where appropriate, secondary sources were cross-checked against primary documents such as clinical trial protocols, regulatory agency summaries, and professional society guideline statements to ensure factual accuracy. Expert validation workshops were used to refine interpretations and to prioritize strategic implications. The methodology emphasized triangulation across evidence streams and transparent documentation of assumptions to provide stakeholders with a credible and actionable synthesis rather than speculative projections.

A synthesis of key conclusions emphasizing integrated evidence, manufacturing agility, and payer collaboration as the determinants of successful therapeutic adoption in gastric oncology

Gastric cancer therapeutics are at an inflection point where scientific opportunity meets complex operational and policy realities. Innovations in targeted therapies, immuno-oncology, and formulation science promise improved outcomes for defined patient populations, yet achieving broad and sustainable access will require deliberate alignment of evidence generation, supply chain strategy, and value demonstration. Stakeholders that proactively invest in diagnostics, agile manufacturing, and pragmatic evidence generation will be better positioned to convert clinical innovation into durable clinical and commercial impact.

Looking ahead, the most successful programs will be those that integrate clinical differentiation with operational readiness and that engage payers and providers early to co-design access pathways. By focusing on these integrated priorities, organizations can reduce uncertainty, accelerate adoption, and ultimately improve therapeutic options for patients living with gastric cancer.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. FDA approval of FGFR2b-targeted monoclonal antibodies driving precision medicine in gastric cancer therapy
• 5.2. Rising adoption of PD-1/PD-L1 immune checkpoint inhibitors in first-line treatment protocols for advanced gastric cancer
• 5.3. Emergence of ctDNA-based liquid biopsy assays enabling real-time monitoring of treatment response in gastric cancer patients
• 5.4. Expansion of HER2-targeted tyrosine kinase inhibitors offering new first-line options for HER2-positive gastric tumors
• 5.5. Increased investment in bispecific antibody candidates addressing dual checkpoint pathways in gastric cancer immunotherapy
• 5.6. Growing focus on microbiome modulation therapies to enhance efficacy of standard chemotherapy regimens in gastric cancer
• 5.7. Strategic partnerships between biopharma and diagnostic firms to develop companion diagnostics for targeted gastric cancer drugs
• 5.8. Advancement of CAR-T cell therapies targeting Claudin 18.2 showing promising durable responses in refractory gastric cancer cases

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastric Cancer Drugs Market, by Therapeutic Class

• 8.1. Biologics
  • 8.1.1. Cytokines
  • 8.1.2. Monoclonal Antibodies
• 8.2. Chemotherapy
  • 8.2.1. Fluoropyrimidines
  • 8.2.2. Platinum-Based Agents
  • 8.2.3. Taxanes
• 8.3. Immunotherapy
  • 8.3.1. Cancer Vaccines
  • 8.3.2. Checkpoint Inhibitors
• 8.4. Targeted Therapy
  • 8.4.1. Her2 Inhibitors
  • 8.4.2. Vegf Inhibitors

9. Gastric Cancer Drugs Market, by Treatment Line

• 9.1. First Line
• 9.2. Second Line
• 9.3. Third Line Or Later

10. Gastric Cancer Drugs Market, by Distribution Channel

• 10.1. Hospital Pharmacies
• 10.2. Retail Pharmacies

11. Gastric Cancer Drugs Market, by Route Of Administration

• 11.1. Intravenous
• 11.2. Oral
• 11.3. Subcutaneous

12. Gastric Cancer Drugs Market, by Dosage Form

• 12.1. Capsules
• 12.2. Lyophilized Powder
• 12.3. Pre-Filled Syringe
• 12.4. Tablets

13. Gastric Cancer Drugs Market, by Therapy Type

• 13.1. Combination Therapy
• 13.2. Monotherapy

14. Gastric Cancer Drugs Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Gastric Cancer Drugs Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Gastric Cancer Drugs Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Merck & Co., Inc.
  • 17.3.2. Bristol-Myers Squibb Company
  • 17.3.3. F. Hoffmann-La Roche Ltd
  • 17.3.4. Eli Lilly and Company
  • 17.3.5. AstraZeneca PLC
  • 17.3.6. Daiichi Sankyo Company, Limited
  • 17.3.7. Pfizer Inc.
  • 17.3.8. Johnson & Johnson
  • 17.3.9. Novartis AG
  • 17.3.10. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. GASTRIC CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 197. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 199. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 201. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 209. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 210. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 215. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 216. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 218. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 220. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 221. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 222. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
• TABLE 224. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 226. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 228. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 230. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 233. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 236. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 237. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 238. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 240. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 241. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 242. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 243. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 244. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
• TABLE 246. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
• TABLE 247. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 248. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 250. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 299. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 300. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 301. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 302. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 303. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 304. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 305. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 306. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 307. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 308. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 309. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 310. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 311. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
• TABLE 312. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
• TABLE 313. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 314. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 315. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 316. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 317. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 318. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 319. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY T